Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed. Initial response was achieved in 25 patients (64%), including 16 patients (43%) with initial parasitological cure. Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes.
Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.
Summary. Tlie life cycle of virulent toxoplasma has been studied in slide cell cultures hy means of continuous observation using phase microscopy. The active penetration of tlu-host cell membrane by the parasite could be dcnionstrated by cinematography. Penetration (lctiir.s within 15 to 30 seconds. The special mode of toxoplasma division called "endotlyogeny" was examined, as well as the development of the rosette-like tenninal colonies of parasites. Virulent toxoplasma destroy their host cells. The free toxoplasma show active mobility and are able to invade new cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.